The American depositary shares of BioNTech SE (BNTX), which made market debut as recently as October 10, 2019, are up an impressive 170 percent based on yesterday's closing price of $44.58.
Germany-based BioNTech is a clinical-stage biotechnology company developing specific immunotherapies for the treatment of cancer and other serious diseases.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com